Tag: Gensight
GenSight Biologics: 1 million euros in cash, visibility until December
(AOF) – GenSight Biologics sees its cash flow horizon extended until October 2023 thanks to the 1st tranche of financing of 10 million euros in August, and until December 2023…
GenSight takes stock!
(Boursier.com) — GenSight Biologics today provides an update on its financial and operational situation. The company has implemented measures to preserve its cash, including a 40% reduction in its workforce,…
GenSight: Disaster?
(Boursier.com) — GenSight , whose quotation should resume today according to a Euronext notice, is expected to fall very sharply after the announcements of the day before. Trading in the…
GenSight: stock market carnage
By Jean-Baptiste André Published on 04/21/2023 at 2:10 p.m. (Boursier.com) — In huge volumes, GenSight collapsed 66%…
Gensight biologics: After its surprise U-turn for its flagship product, biotech GenSight collapses on the stock market
(BFM Bourse) – The company has chosen to abandon the process to obtain marketing authorization for Lumevoq from the European Medicines Agency. GenSight plans to produce new clinical data, which…
Gensight Biologics collapses after Lumevoq clearance request withdrawn – 04/21/2023 at 14:46
Lumevoq is a gene therapy treatment for Leber hereditary optic neuropathy (LHON). (illustration photo / Photo credits: Adobe Stock – ) (AOF) – GenSight Biologics loses 65.96% to 0.8340 euro…
GenSight Biologics: Lumevoq early access data confirms clinical trials – 03/15/2023 at 09:57
(AOF) – GenSight Biologics announces that the efficacy and safety data of patients with Leber Hereditary Optic Neuropathy (LHON) and carriers of the ND4 mutation treated with lenadogene nolparvovec (or…
GenSight Biologics: presentation of data on LUMEVOQ – 03/15/2023 at 10:28
(CercleFinance.com) – GenSight Biologics announces today that the efficacy and safety data of patients with Leber Hereditary Optic Neuropathy and carriers of the ND4 mutation treated with lenadogene nolparvovec (LUMEVOQÒ,…
GenSight Biologics: presentation of data on LUMEVOQ
(CercleFinance.com) – GenSight Biologics announces today that the efficacy and safety data of patients with Leber Hereditary Optic Neuropathy and carriers of the ND4 mutation treated with lenadogene nolparvovec (LUMEVOQÒ,…
GenSight Biologics: positive 3-year data for Lumevoq
(CercleFinance.com) – GenSight Biologics today announces efficacy and safety results at 3 years post-injection of Lumevoq in the REFLECT phase III clinical trial. The results show the maintenance of the…
GenSight Biologics: will present data on Lumevoq – 03/10/2023 at 10:15 am
(CercleFinance.com) – GenSight Biologics announces today that the Company will participate and present data on LUMEVOQ at medical conferences in the coming weeks. On Tuesday, March 14, Dr. Catherine Vignal,…
GenSight Biologics: will present data on Lumevoq
(CercleFinance.com) – GenSight Biologics announces today that the Company will participate and present data on LUMEVOQ at medical conferences in the coming weeks. On Tuesday, March 14, Dr. Catherine Vignal,…